• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

    19.57 -0.01 (-0.05%)
    Delayed Quote Updated: 10:28 AM EDT, Oct 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,404
    Open 19.53
    Bid (Size) 19.44 (200)
    Ask (Size) 19.76 (200)
    Prev. Close 19.58
    Today's Range 19.32 - 19.71
    52wk Range 8.672 - 22.88
    Shares Outstanding 14,828,456
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Anika (ANIK) Q2 2026 Earnings Call Transcript ↗
    Revenue hit $32.6 million with record commercial channel sales and expanded margins. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
    Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU) 
    From American News Group
    Via GlobeNewswire

    Performance

    52-Week Range 14.5% below 52-week high
    19.57
    8.6752W Low 22.8852W High
    1 Week 1.9% below 1-week high
    18.111W Low 19.951W High

    Anika Therapeutics Inc. - Common Stock (ANIK) traded between $8.67 and $22.88 over the past 52 weeks and last traded at $19.57, 14.5% below its 52-week high. Over the past week it ranged between $18.11 and $19.95.

    Past 12 Months
    -0.8%
    -6.2%
    +24.1%
    +31.4%
    +109.3%
    +115.1%
    1W -$0.16
    1M -$1.29
    3M +$3.80
    6M +$4.68
    YTD +$10.22
    1Y +$10.47

    ANIK was +115.1% over the past year, +31.4% over six months, +109.3% year to date, -0.8% in the last week.

    12 Months vs Market
    ANIK
    +115.1%
    DIA
    +12.5%
    SPY
    +17.3%
    QQQ
    +23.9%
    IWM
    +13.8%

    Over the past 12 months ANIK returned +115.1% versus DIA (Dow) +12.5%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +23.9% and IWM (Russell 2000) +13.8%.

    Volume & Liquidity 0.04× 3-mo avg
    Today 4,404 3-mo avg 100.4K
    1W
    117.0K
    1M
    91.1K
    3M
    100.4K
    6M
    96.9K
    YTD
    113.1K
    1Y
    120.7K

    ANIK most recently traded 4,404 shares against a 3-month average daily volume of 100.4K.

    More News

    Read More
    News headline image
    Anika Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Anika Therapeutics (NASDAQ:ANIK) Soars on Q2 Earnings Beat, Revenue and EPS Top Estimates ↗
    Via Chartmill
    Topics Earnings
    Anika Therapeutics Inc (NASDAQ:ANIK) Soars on Q1 Earnings and Revenue Beat ↗
    Via Chartmill
    ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Delivers Decisive Q4 2025 Earnings Beat, Sparking Share Rally ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
    From TELA Bio, Inc.
    Via GlobeNewswire
    News headline image
    Anika (ANIK) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Anika (ANIK) Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Anika (ANIK) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
    From Xilio Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
    Via MarketMinute
    News headline image
    Telix Strengthens Board with Additional Director Appointments
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.
    From Kirby McInerney LLP
    Via Business Wire
    News headline image
    Anika Therapeutics Announces Leadership Transition
    From Anika Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
    From Kirby McInerney LLP
    Via Business Wire
    News headline image
    Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
    From Kirby McInerney LLP
    Via GlobeNewswire
    News headline image
    Anika (ANIK) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings

    Frequently Asked Questions

    Is Anika Therapeutics Inc. - Common Stock publicly traded?
    Yes, Anika Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Anika Therapeutics Inc. - Common Stock trade on?
    Anika Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Anika Therapeutics Inc. - Common Stock?
    The ticker symbol for Anika Therapeutics Inc. - Common Stock is ANIK on the Nasdaq Stock Market
    What is the current price of Anika Therapeutics Inc. - Common Stock?
    The current price of Anika Therapeutics Inc. - Common Stock is 19.57
    When was Anika Therapeutics Inc. - Common Stock last traded?
    The last trade of Anika Therapeutics Inc. - Common Stock was at 10/12/26 10:28 AM ET
    What is the market capitalization of Anika Therapeutics Inc. - Common Stock?
    The market capitalization of Anika Therapeutics Inc. - Common Stock is 290.19M
    How many shares of Anika Therapeutics Inc. - Common Stock are outstanding?
    Anika Therapeutics Inc. - Common Stock has 290M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.